Modality
Vaccine
MOA
Anti-Tau
Target
SMN2
Pathway
STING
CKDETCTCL
Development Pipeline
Preclinical
Feb 2019
→ Dec 2026
PreclinicalCurrent
NCT03591078
1,594 pts·CTCL
2019-02→2026-12·Not yet recruiting
NCT05325739
159 pts·CTCL
2021-03→2026-12·Active
1,753 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-068mo awayInterim· CTCL
2026-12-249mo awayInterim· CTCL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2026-12-06 · 8mo away
CTCL
Interim
2026-12-24 · 9mo away
CTCL
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03591078 | Preclinical | CTCL | Not yet recr... | 1594 | PANSS |
| NCT05325739 | Preclinical | CTCL | Active | 159 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |